Since 2001, the International Myeloma Working Group’s achievements have changed the landscape of myeloma research. This collaborative effort has brought about breakthroughs in treatment options and diagnostic systems that prolong lives. The IMWG consists of nearly 200 leading myeloma researchers from around the world who collaborate on a broad range of myeloma research projects. Their work focuses on protocols to provide a more durable remission for myeloma patients while improving quality of life, and addressing the needs of both myeloma patients and the physicians who treat them.

IMWG Publications

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth of

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p),

  • International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Recommendations developed by the International Myeloma Working Group (IMWG), the research arm of the IMF, were published online in the Journal of Clinical Oncology on March 14, 2016. The